grant

Stromal-immune cell crosstalk promotes autoimmune valvular carditis

Organization UNIVERSITY OF MINNESOTALocation MINNEAPOLIS, UNITED STATESPosted 14 Nov 2024Deadline 31 Oct 2026
NIHUS FederalResearch GrantFY20256-C-kine6-Ckine6CkineAblationAntibodiesArthritisAutoantibodiesAutoimmuneB blood cellsB cellB cellsB-Cell ActivationB-CellsB-LymphocytesB-cellBasal Transcription FactorBasal transcription factor genesBody TissuesCCL-21 chemokineCCL21CCL21 geneCKb9CSF-1Cardiac ValvesCarditisCell BodyCell CommunicationCell Growth in NumberCell InteractionCell MultiplicationCell ProliferationCell-to-Cell InteractionCellsCellular ProliferationChemotactic CytokinesChronicColony-Stimulating Factor 1CommunicationDNA Synthesis FactorDataDeveloping CountriesDeveloping NationsDevelopmentDiseaseDisorderDissectionDysfunctionEndothelial Cell Growth FactorEndothelial CellsExodus-2 chemokineFGFFibroblast Growth FactorFibroblast Growth Factor Gene FamilyFibroblast Growth Regulatory FactorFibroblastsFibrosisFibrosis in the heartFibrosis in the myocardiumFibrosis within the heartFibrosis within the myocardiumFibrotic myocardiumFunctional disorderGeneral Transcription Factor GeneGeneral Transcription FactorsGeneralized GrowthGenesGoalsGrowthGrowth AgentsGrowth FactorGrowth SubstancesHeart Valve DiseasesHeart ValvesHeart failureHomologous Chemotactic CytokinesHumanImmuneImmune systemImmunesImpairmentInflammationIntercrinesInterventionInvadedKO miceKnock-out MiceKnockout MiceLaboratoriesLess-Developed CountriesLess-Developed NationsLigandsLoxP-flanked alleleLupus Erythematosus DisseminatusLymphaticLymphatic Endothelial CellsLymphatic cellLymphatic functionLymphocyteLymphocyticM-CSFMGC34555MacrophageMacrophage Colony-Stimulating FactorMediatingMediatorMiceMice MammalsModern ManMolecularMurineMusMusculoskeletal Pain DisorderMyocarditisNatureNull MouseOrganPDGFPDGF ReceptorsPathogenicityPathological ConstrictionPathologyPathway interactionsPatient CarePatient Care DeliveryPatientsPhysiologicPhysiologicalPhysiologyPhysiopathologyPlatelet-Derived Growth FactorPlatelet-Derived Growth Factor ReceptorPopulationPositionPositioning AttributeProductionProliferatingProteins Growth FactorsRheumatic DiseasesRheumatic Heart DiseaseRheumatismRheumatologic DiseasesRheumatologic DisorderRoleSCYA21SIS cytokinesSLCSLC proteinSLESecondary Lymphoid Tissue ChemokineSmall Inducible Cytokine A21StenosisStromal CellsSurfaceSurgical ValvesSystemic Lupus ErythematosusSystemic Lupus ErythematousSystemic Lupus ErythmatosusTCA4TCA4 proteinTestingThird-World CountriesThird-World NationsTimeTissue GrowthTissuesTranscription Factor Proto-OncogeneTranscription factor genesTranslatingUnder-Developed CountriesUnder-Developed NationsValvular Heart DiseasesValvular Heart DisorderVascular Endothelial CellWorkactivated B cellsarthriticautoimmune antibodyautoreactive antibodycardiac failurecardiac fibrosiscardiac inflammationcardiac valve diseasecardiac valve disordercardiac valvular diseasecare for patientscare of patientscaring for patientscell typechemoattractant cytokinechemokineconditional knock-outconditional knockoutcoronary fibrosiscytokinedegenerative valvular heart diseasedesigndesigningdeveloping countrydeveloping nationdevelopmentaldisseminated lupus erythematosusexodus-2experienceexperimentexperimental researchexperimental studyexperimentsfibrotic heartfloxedfloxed alleleheart fibrosisheart valve disorderhuman diseaseimprovedinsightinterstitial cellknockout genelymph celllymph channellymph vessellymphatic channellymphatic valvelymphatic vesselmouse modelmurine modelmyocardial fibrosisnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetontogenypathophysiologypathwaypublic health relevancerecruitrepairrepairedresponseself reactive antibodysocial rolesource localizationsystemic autoimmunitysystemic lupus erythematosistargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmentthymus-derived chemotactic agent 4transcription factor
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

ABSTRACT: STROMAL-IMMUNE CELL CROSSTALK PROMOTES AUTOIMMUNE VALVULAR CARDITIS
Understanding how immune cells and stromal cells interact and communicate with one another is critical in

both normal physiology and pathophysiologic states. Such interactions dictate whether, in the face of a

perturbation, the tissues will eventually return to normal physiologic function or whether the tissue will

experience chronic changes such as fibrosis that may impact tissue and organ function. This proposal focuses

on immune-stromal cell interactions in the cardiac valves. In human diseases including rheumatic heart

disease (RHD), systemic lupus erythematosus, and related immune-driven conditions, the cardiac valves

become inflamed. Over time, chronic inflammation leads to fibrosis, resulting in dysfunction of the valves and

culminating eventually in heart failure. Therapies are currently limited, involving primarily surgical valve repair

or replacement. Our laboratory has pioneered a mouse model of autoantibody-driven valvular carditis

resembling these human conditions. We have shown key roles for particular immune cells (macrophages and

B cells) as well as stromal cells (fibroblasts and endothelial cells). This proposal focuses on defining the

pathways by which these immune and stromal cells communicate to perpetuate disease. In the first Aim, we

will investigate whether fibroblasts – termed valve interstitial cells (VICs) – promote macrophage-mediated

inflammation by producing the growth factor CSF-1. We will also determine if PDGF, produced primarily by

immune cells, promotes VIC proliferation and activation to drive valve fibrosis. The second Aim builds on our

recent description of new lymphatic endothelial cells and vessels emerging in the inflamed cardiac valves in

this mouse model. The function of these lymphatic vessels remains incompletely defined. Building on our

preliminary data, we will explore the hypothesis that these lymphatic endothelial cells produce the chemokine

CCL21 that interacts with CCR7-expressing B cells to perpetuate local autoantibody-driven pathology in the

cardiac valves. The proposed experiments involve conditional gene knockout approaches designed to provide

cell-type specific mechanistic insight regarding these stromal-immune cell crosstalk pathways. Our studies will

be the among the first to investigate these cellular communication pathways in the context of immune-

mediated valvular carditis and to explore the function of the valve lymphatics we recently characterized.

Furthermore, we have focused on pathways for which novel therapies are currently being developed, with the

hope that identification of key molecular pathways could be translated rapidly to improve care for patients with

RHD and related conditions.

Grant Number: 1R21AI187243-01
NIH Institute/Center: NIH

Principal Investigator: Bryce Binstadt

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →